Rxivist logo

Author: David Cooper

  • Most recently observed institution: Pfizer

Rankings

  • All-time downloads: 252,331 (rank: 152 )
  • Categories:
    • infectious diseases: 166,061 (rank: 96 (tie) )
    • microbiology: 86,270 (rank: 166 (tie) )

Downloads per author, site-wide

Preprints

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

infectious diseases more details view paper
  • Downloaded 67,370 times
  • Download rankings, all-time:
    • Site-wide: 75
    • In infectious diseases: 30
  • Year to date:
    • Site-wide: 214
  • Since beginning of last month:
    • Site-wide: 321

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

infectious diseases more details view paper
  • Downloaded 63,902 times
  • Download rankings, all-time:
    • Site-wide: 83
    • In infectious diseases: 32
  • Year to date:
    • Site-wide: 74
  • Since beginning of last month:
    • Site-wide: 136

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

microbiology more details view paper
  • Downloaded 55,739 times
  • Download rankings, all-time:
    • Site-wide: 96
    • In microbiology: 8
  • Year to date:
    • Site-wide: 5
  • Since beginning of last month:
    • Site-wide: 127

Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera

microbiology more details view paper
  • Downloaded 30,531 times
  • Download rankings, all-time:
    • Site-wide: 208
    • In microbiology: 19
  • Year to date:
    • Site-wide: 19
  • Since beginning of last month:
    • Site-wide: 32

Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine

infectious diseases more details view paper
  • Downloaded 22,729 times
  • Download rankings, all-time:
    • Site-wide: 296
    • In infectious diseases: 110
  • Year to date:
    • Site-wide: 432
  • Since beginning of last month:
    • Site-wide: 479

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

infectious diseases more details view paper
  • Downloaded 12,060 times
  • Download rankings, all-time:
    • Site-wide: 626
    • In infectious diseases: 203
  • Year to date:
    • Site-wide: 104
  • Since beginning of last month:
    • Site-wide: 182

PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News